SCHEMBL6750713

SCHEMBL6750713

CN1C(=O)C(Cc2ccc(-c3ccccc3)cc2)Cc2cc(C(=O)OCc3cccc(F)c3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
MAPT P10636 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
SRD5A1 P18405 1/20 0.40
SRD5A2 P31213 1/20 0.40
MMP1 P03956 2/20 0.40
MMP2 P08253 2/20 0.40
MMP12 P39900 2/20 0.40
MMP9 P14780 1/20 0.40
FOLH1 Q04609 5/20 0.38
GAA P10253 1/20 0.38
STAT1 P42224 1/20 0.38
PKM P14618 1/20 0.38
GPBAR1 Q8TDU6 1/20 0.38
BCHE P06276 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7927907 0.69 SRD5A1 (0.55) MAPTRAB9ANPC1SRD5A1SRD5A2
SCHEMBL6747401 0.69 PTK2 (0.38) MAPTMMP1MMP2MMP12MMP9
SCHEMBL30489343 0.68 DRD2 (0.46) MAPTRAB9ANPC1GAAPKM
SCHEMBL28995160 0.68 DRD2 (0.46) MAPTRAB9ANPC1GAAPKM
SCHEMBL28117924 0.68 KMT2A (0.69) KDM4EMAPTCYP1A2CYP2D6CYP2C9
SCHEMBL5336730 0.67 KDM4E (0.67) KDM4EMAPTCYP1A2CYP2D6CYP2C9
SCHEMBL6745728 0.67 F2 (0.54) MAPTRAB9ANPC1SRD5A1SRD5A2
SCHEMBL20119309 0.66 TDP1 (0.69) KDM4EMAPTCYP1A2CYP2D6CYP2C9
SCHEMBL6953267 0.65 ITGB3 (0.52) MAPTRAB9ANPC1SRD5A1SRD5A2
SCHEMBL6953271 0.65 ITGB3 (0.52) MAPTRAB9ANPC1SRD5A1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043984-A1 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors O'BRIEN PATRICK MICHAEL (US) 2004-03-04 US disclosed
WO-2004014389-A1 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043984-A1 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors MMP13, MMP9, MMP3 KDM4E 1367/4885MAPT 1797/4885CYP1A2 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.